Navigation Links
GlaxoSmithKline Obtains Exclusive U.S. OTC Marketing Rights to MEVACOR(R) (lovastatin) from Merck & Co., Inc.
Date:11/26/2007

x) similar to that seen with the 60 mg/kg/day dose.

CNS vascular lesions, characterized by perivascular hemorrhage and edema, mononuclear cell infiltration of perivascular spaces, perivascular fibrin deposits and necrosis of small vessels, were seen in dogs treated with lovastatin at a dose of 180 mg/kg/day, a dose which produced plasma drug levels (Cmax) which were about 30 times higher than the mean values in humans taking 80 mg/day.

Similar optic nerve and CNS vascular lesions have been observed with other drugs of this class.

Cataracts were seen in dogs treated for 11 and 28 weeks at 180 mg/kg/day and 1 year at 60 mg/kg/day.

Carcinogenesis, Mutagenesis, Impairment of Fertility

In a 21-month carcinogenic study in mice, there was a statistically significant increase in the incidence of hepatocellular carcinomas and adenomas in both males and females at 500 mg/kg/day. This dose produced a total plasma drug exposure 3 to 4 times that of humans given the highest recommended dose of lovastatin (drug exposure was measured as total HMG-CoA reductase inhibitory activity in extracted plasma). Tumor increases were not seen at 20 and 100 mg/kg/day, doses that produced drug exposures of 0.3 to 2 times that of humans at the 80 mg/day dose. A statistically significant increase in pulmonary adenomas was seen in female mice at approximately 4 times the human drug exposure. (Although mice were given 300 times the human dose [HD] on a mg/kg body weight basis, plasma levels of total inhibitory activity were only 4 times higher in mice than in humans given 80 mg of MEVACOR.)

There was an increase in incidence of papilloma in the non-glandular mucosa of the stomach of mice beginning at exposures of 1 to 2 times that of humans. The glandular mucosa was not affected. The human stomach contains only glandular mucosa.

In a 24-month carcinogenicity study in rats, there was a positive dose response relationship for hepatocellular carcinogeni
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related medicine news :

1. GlaxoSmithKline Responds to JAMA Articles
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Congressional Black Caucus Foundation and GlaxoSmithKline Announce Supplier Business Initiative Study Results
4. AUDIO from Medialink and GlaxoSmithKline: A New Nasal Spray for Allergy Relief
5. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
6. GlaxoSmithKline Aids California Fire Relief Efforts
7. Genmab and GlaxoSmithKline Initiate Ofatumumab Rheumatoid Arthritis Phase III Program
8. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
9. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
10. Crdentias VP of Marketing, Christina Hogan, Provides Exclusive Interview on Marketing Strategy
11. Pearson VUE Signs Exclusive Contract with Educational Resources, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Responding to the call to ... to an increasingly diverse patient population, three leading ... expertise to the publication of a new textbook ... and Cultural Competence in Health Care: A Systems ... a professor in the Management Division at the ...
(Date:7/30/2014)... returning National Guard soldiers were more likely to ... life setbacks, including job loss, legal problems, divorce, ... military families. Results of the study by researchers ... are published online in the American Journal ... a major concern for reservists returning home. Nearly ...
(Date:7/30/2014)... Recently, the Kansas Health Image ... start-up fees for hospitals and clinics who request ... September 30, 2014. , Modern healthcare providers are ... complexity of digital patient information, often referred to ... data silos. , Traditional health IT solutions, including ...
(Date:7/30/2014)... 2014 MyMobileUniversity (MMU) is a global ... an award winning mobile and web based learning company ... 2004. , MyMobileUni.com’s platform makes it a one-stop centre ... has links to the world’s leading Massive Open Online ... experts from all over the world who have content ...
(Date:7/30/2014)... Daily Gossip mentions that the "Panic Away" method developed ... stop anxiety and eliminate all associated symptoms. It has been ... 150,000 people in getting their lives back. , The Panic ... system that will teach sufferers different techniques on how to ... to access, as it is available in a complex guide. ...
Breaking Medicine News(10 mins):Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 2Health News:NLN CEO Co-Authors Textbook to Advance Diversity and Cultural Competence Across Health Care Professions 3Health News:Vets' alcohol problems linked to stress on the home front 2Health News:Kansas Health Image Exchange Announces Open Enrollment; Virtual CD from Offsite Image Solves Problems with Unreadable Patient Images, Delayed Diagnosis 2Health News:Kansas Health Image Exchange Announces Open Enrollment; Virtual CD from Offsite Image Solves Problems with Unreadable Patient Images, Delayed Diagnosis 3Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 2Health News:MyMobileUniversity Inviting Individuals, Who Are Passionate about the Universal Right to Education, to Come on Board as Goodwill Ambassadors 3Health News:Panic Away Review Reveals How to Stop Anxiety 2
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that Dr. Neil Sadick ... the American Academy of Dermatology in San Antonio, ... Dr. Sadick, a prominent New York,dermatologist, outlined the ...
... patients receiving aggressive drug therapy to cut blood sugar ... large North American trial designed to aggressively lower the ... heart disease has been halted because of an unexpected ... , Federal health officials announced Wednesday that 257 ...
... Senetek PLC (OTC,Bulletin Board: SNKTY), a Life ... target the science of healthy aging, today announced,the ... ., Mr. Frank Massino, Senetek,s Chairman and ... greater visibility to Senetek at this,significant time in ...
... Introduced during the much anticipated ... America., TORONTO, Feb. 6 /PRNewswire/ - IgeaCare Systems ... introduction of,ConversationPRO(TM) for Microsoft Dynamics CRM 4.0., "Contact ... CRM,screen launch populated with the caller contact information, along ...
... ST. LOUIS, Feb. 6 Cejka Search, ... firm, recently announced that,several of its leaders ... Retention Strategies Audio Conference and the American,College ... Leadership., Audio Conference: Retention Strategies to ...
... CHAPEL HILL, N.C., Feb. 6 From ... improvements, customer feedback has,enhanced services, products and ... recent study by Best Practices, LLC,s Global ... initiatives is key,to better aligning the customer ...
Cached Medicine News:Health News:Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology 2Health News:Deaths Halt Part of Large Diabetes Trial 2Health News:Deaths Halt Part of Large Diabetes Trial 3Health News:Deaths Halt Part of Large Diabetes Trial 4Health News:Senetek PLC Announces Launch of New Website 2Health News:Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc. 2Health News:Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc. 3Health News:Cejka Search Experts Present Latest Developments in Physician Retention and CEO Leadership Skills 2Health News:Customer Experience Conference, Feb. 25-27: Sharing New Insights on Winning Customer Loyalty 2
(Date:7/30/2014)... July 30, 2014  Cepheid (Nasdaq: ... contract with Premier will end on September 30, ... will be able to continue their relationship with ... MedAssets, Novation, and ROi, in addition to the ... Cepheid. "Cepheid has always recognized and ...
(Date:7/30/2014)... , July 30, 2014 PuraMed ... and marketer of over-the-counter (OTC) medicinal and healthcare ... ® M name along with the name,s ... replaced with the trademarked name MigraPure ® ... palette of PuraMed,s homeopathic, natural migraine pain reliever ...
(Date:7/30/2014)... July 30, 2014 Research and Markets ... and Chinese Aseptic Packaging Industry Report 2014" report ... The Global and Chinese Aseptic Packaging ... the current state of the global Aseptic Packaging industry ... report provides a basic overview of the industry including ...
Breaking Medicine Technology:Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 2Cepheid Updates Status Of Premier Group Purchasing Organization (GPO) Agreement 3PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Global and Chinese Aseptic Packaging Industry Report 2014 2
... LOUIS, Aug. 30, 2011 The Board of Directors of ... its regularly scheduled board meeting that it reaffirmed the Company,s ... platform and expansion of the Odyssey ™  platform into ... Board reviewed and endorsed the commercial strategies put forth for ...
... 30, 2011 Reportlinker.com announces that a new ... catalogue: Specialty Pharmaceutical Industry ... http://www.reportlinker.com/p0512130/Specialty-Pharmaceutical-Industry---2011-Yearbook.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology Summary ... - 2011 Yearbook" essentially provides insights on ...
Cached Medicine Technology:Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 2Stereotaxis' Board of Directors Reaffirms Commercialization Plans for Epoch™ and Odyssey™ Product Platforms 3Specialty Pharmaceutical Industry - 2011 Yearbook 2Specialty Pharmaceutical Industry - 2011 Yearbook 3Specialty Pharmaceutical Industry - 2011 Yearbook 4Specialty Pharmaceutical Industry - 2011 Yearbook 5Specialty Pharmaceutical Industry - 2011 Yearbook 6Specialty Pharmaceutical Industry - 2011 Yearbook 7Specialty Pharmaceutical Industry - 2011 Yearbook 8Specialty Pharmaceutical Industry - 2011 Yearbook 9Specialty Pharmaceutical Industry - 2011 Yearbook 10Specialty Pharmaceutical Industry - 2011 Yearbook 11Specialty Pharmaceutical Industry - 2011 Yearbook 12Specialty Pharmaceutical Industry - 2011 Yearbook 13Specialty Pharmaceutical Industry - 2011 Yearbook 14Specialty Pharmaceutical Industry - 2011 Yearbook 15Specialty Pharmaceutical Industry - 2011 Yearbook 16
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
For the quantitative in vitro determination of K-glutamyl transferase (K-GT) in serum or plasma....
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
Medicine Products: